Cempra's solithromycin meets primary and secondary objectives in Phase III trial

US-based pharmaceutical firm Cempra has reported positive topline results from a global, pivotal Phase III clinical trial of solithromycin oral capsules (Solitaire-Oral) in the treatment of patients with community acquired bacterial pneumonia (CABP).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news